
Retension Pharmaceuticals and TRex Bio filed for United States initial public offerings on Friday morning, adding breadth to the autumn IPO window. The dual filings follow a wave of biotech acquisitions by large drugmakers. Biotech listings have proven resilient against broader market pressures.






